Dr. Alexandre Carbonnel is an expert in competition and regulatory economics who started his career at the Competition and Markets Authority predecessor (Office of Fair Trading) in London before working as a consultant in Brussels and Paris. He advises clients in the context of investigations by the European Commission and national competition authorities and provides support on the estimation of damages in the context of commercial litigation, serving as a testifying expert in high-profile disputes. In competition economics, Dr. Carbonnel advises clients on matters such as cartels and exchanges of information, abuse of dominance, and merger control. His experience covers key sectors and industries, including pharmaceuticals, retail, e-commerce, agro-alimentary products, and logistics, as well as network industries such as gas, electricity, and telecoms. Dr. Carbonnel has contributed to economic reports advising national authorities on competition issues and counseling the European Commission on intellectual property rights. He publishes regularly on topics related to competition and lectures on competition economics at HEC Paris. At the Office of Fair Trading, Dr. Carbonnel notably worked on a high-profile case involving anti-competitive practices in the pharmaceutical industry (the Paroxetine case) and on the assessment of Phase 1 mergers such as LSE/LCH.Clearnet and AG Barr/Britvic, among other matters. Dr. Carbonnel holds a PhD in economics, a Master’s degree in mathematical economics and econometrics from the Toulouse School of Economics, and a BA in economics from the University of Lausanne (HEC Lausanne). During his doctoral studies, he was a university lecturer in economics at the Toulouse School of Economics and in the Law School of Toulouse I University.
19546 | Évènements
During the launch of its pharmaceutical sector inquiry in November 2017, the French Competition Authority (FCA) expressed interest in the discounts granted by generics firms to pharmacies. The FCA quoted the decision issued following the previous sector inquiry carried out in 2013, which "had (...)